Addus HomeCare (ADUS) Set to Announce Earnings on Tuesday

Key Points

• Addus HomeCare is expected to report Q3 2026 results after Tuesday’s market close. Analysts forecast earnings of $1.79 per share on revenue of $388.72 million; the earnings call is scheduled for November 4 at 9:00 a.m. ET.
• In the prior quarter, Addus posted EPS of $1.73, exceeding estimates by $0.03, while revenue rose 8.0% year over year to $377.41 million.
• The stock recently traded at $121.17, near its 52-week high, while analysts maintain a consensus “Moderate Buy” rating and an average price target of $129.33.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $1.79 per share and revenue of $388.72 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 9:00 AM ET.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.73 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.70 by $0.03. Addus HomeCare had a net margin of 7.13% and a return on equity of 9.96%. The company had revenue of $377.41 million for the quarter, compared to analyst estimates of $376.24 million. During the same quarter last year, the firm posted $1.49 earnings per share. The business's quarterly revenue was up 8.0% on a year-over-year basis. On average, analysts expect Addus HomeCare to post $6.33 EPS for the current fiscal year and $6.78 EPS for the next fiscal year.

Addus HomeCare Trading Down 0.5%

NASDAQ ADUS opened at $121.17 on Tuesday. The stock has a market cap of $2.26 billion, a P/E ratio of 21.26, a PEG ratio of 1.73 and a beta of 0.83. The company's fifty day simple moving average is $116.61 and its 200-day simple moving average is $106.22. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.05. Addus HomeCare has a 52 week low of $87.95 and a 52 week high of $124.43.

Analysts Set New Price Targets

ADUS has been the topic of a number of recent analyst reports. Barclays boosted their price objective on shares of Addus HomeCare from $92.00 to $96.00 and gave the stock an "underweight" rating in a report on Wednesday, July 8th. Weiss Ratings upgraded Addus HomeCare from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, September 24th. Bank of America restated a "neutral" rating and set a $125.00 target price (down from $140.00) on shares of Addus HomeCare in a research note on Monday, September 14th. Citigroup lowered Addus HomeCare from a "market outperform" rating to a "neutral" rating in a research report on Monday, September 14th. Finally, Raymond James Financial set a $137.00 price target on Addus HomeCare in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $129.33.

Addus HomeCare Company Profile

Addus HomeCare Inc NASDAQ: ADUS provides in-home personal care, hospice and home health services to older adults, people with disabilities and other individuals who need assistance with daily living or medical care. Its services are designed to help clients remain safely and independently in their homes while supporting families and caregivers.

The company's personal care services include assistance with bathing, dressing, grooming, meal preparation, housekeeping and other activities of daily living.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.